While exploratory, our study suggests that PRS may not be as relevant for carriers of PD-related pathogenic variants such as GBA p.N370S or LRRK2 p.G2019S and other PD high risk variants on predicting DBS treatment response and may be confounding the PRS analysis results. This evidence concerns the gene GBA1 and Parkinson disease.